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Tissue-specific stem cells found in adult tissues can participate in the repair process following injury. How-
ever, adult tissues, such as articular cartilage and intervertebral disc, have low regeneration capacity, whereas
fetal tissues, such as articular cartilage, show high regeneration ability. The presence of fetal stem cells in
fetal cartilaginous tissues and their involvement in the regeneration of fetal cartilage is unknown. The aim
of the study was to assess the chondrogenic differentiation and the plasticity of fetal cartilaginous cells. We
compared the TGF-β3-induced chondrogenic differentiation of human fetal cells isolated from spine and
cartilage tissues to that of human bone marrow stromal cells (BMSC). Stem cell surface markers and adipo-
genic and osteogenic plasticity of the two fetal cell types were also assessed. TGF-β3 stimulation of fetal
cells cultured in high cell density led to the production of aggrecan, type I and II collagens, and variable
levels of type X collagen. Although fetal cells showed the same pattern of surface stem cell markers as
BMSCs, both type of fetal cells had lower adipogenic and osteogenic differentiation capacity than BMSCs.
Fetal cells from femoral head showed higher adipogenic differentiation than fetal cells from spine. These
results show that fetal cells are already differentiated cells and may be a good compromise between stem
cells and adult tissue cells for a cell-based therapy.
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INTRODUCTION availability of the cells, their in vitro amplification, as
well as their regeneration capacity can hamper the feasi-
bility of these techniques (11,16,25).Degeneration of cartilaginous tissues such as articular
cartilage and intervertebral disc leads to disability, de- The use of mesenchymal stem cells (MSC) opened
new opportunities in treating different tissue such ascreased quality of life, and higher medical costs. Cell-
based therapies for cartilaginous tissue regeneration are nerve (46), bone (47), or for cartilaginous tissue regen-
eration (27,42,43). MSCs can be retrieved from bonean attractive prospective as they allow potential forma-
tion of a functional tissue. Autologous cell transplanta- marrow or adipose tissue with minimally invasive proce-
dures and can be differentiated in vitro towards chondro-tion has first been investigated for immunocompatibility
reasons. Autologous chondrocyte transplantation is clin- genic, osteogenic, or adipogenic phenotypes (2,18,44).
Adult MSCs can only be differentiated into a limitedically applied for full-thickness cartilage lesions and au-
tologous disc cell transplantation has also been effected number of phenotypes, whereas embryonic stem cells
can virtually be differentiated into all phenotypes. Tran-in clinical trials (6,7,28,33). Although these methods
achieve good clinical results, limitations regarding the sition from embryonic to adult stage involves the prolif-
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eration and the specialization of embryonic cells under minced in small pieces. Fetal spine units, composed of
one intervertebral disc and the two adjacent vertebrae,the control of morphogens. As cells become specialized,
they lose their differentiation potential. The presence of were minced in small pieces with a scalpel and put into
culture in DMEM (Gibco, Switzerland) supplementedtissue-specific stem cells in various adult tissues shows
that unspecialized cells remain in adult tissues (36). In with 10% fetal bovine serum (FBS) and 1% 100 mM L-
glutamine (Gibco) (hereafter referred to as growth me-case of tissue injury, these cells can proliferate, differen-
tiate, and regenerate the damaged tissue. However, the dium) at 37°C under 5% CO2. Femoral heads of fetal
femurs were isolated, minced in small pieces with apercentage of tissue-specific stem cells has been shown
to decrease with age, concomitantly to regeneration po- scalpel, and put into culture in the same conditions as
for fetal spine cells. For both tissues, cells migrated fromtential of these tissues (9).
Fetal tissues, including articular cartilage, have high the minced pieces, adhered to the plastic dishes, and be-
gan to proliferate. When primary cultures reached 80%regeneration capacity, which seems inherent to fetal
cells and not dependant on the local environment in the confluency, cells were detached with trypsin/EDTA and
plated in T75 flask in growth medium for further cellwomb (26,31,38). Specific mechanisms involved in fetal
cartilage regeneration are still largely unknown. Particu- expansion (passage 1). When cells reached 80% conflu-
ency, cells were detached by trypsin/EDTA, mixed to-larly, the presence of fetal stem cells in fetal cartilage
and their involvement in the fetal regeneration process gether to ensure consistency, and stored in frozen vials
of cells at passage 1. Thus, a dedicated and consistentis unknown. Fetal stem cells have already been isolated
from fetal tissues such as bone marrow, lung, liver, cell bank was established from each biopsy as described
in De Buys Roessingh et al. (12) and Quintin et al. (35).spleen, and umbilical cord (8,22,23). In addition, as fetal
cells are in an intermediate stage of development be- For experiments, frozen vials were thawed and cells
were expanded in monolayer and used for experimentstween undifferentiated embryonic cells and specialized
adult cells, questions remain about their degree of differ- at passage 4 unless otherwise stated. Human bone mar-
row stromal cells (BMSC) isolated from iliac crest boneentiation and their plasticity potential, that is to say that
their capacity to transdifferentiate into multiple lineages. marrow by plastic adherence selection (n = 2, aged 19
and 28 years) were kindly provided by Dr. Ivan MartinFetal tissues offer very low immunogenic properties,
which are closely dependent on the organ and gesta- from Basel University. MSCs were cultured in MSC me-
dium consisting of α-MEM (Gibco) supplemented withtional age (15). As for fetal tissues, fetal cells showed
immunogenic properties, which can be partially ex- 10% FBS, 1% 100 mM L-glutamine, and freshly added
10 ng/ml fibroblast growth factor (FGF; Sigma, Switzer-plained by a low level of expression of HLA-I and the
absence of HLA-II expression (1,17,20,29). As fetal land). Cells were used in experiments between passages
3 and 6.cells offer low immunogenicity, good regeneration prop-
erties, and are readily cultured in vitro, they are good
FACS Analysis of Surface Markerscandidates to be used for a cell-based therapy (15,20,
34,35). Fetal cells at passage 0 were thawed and cultured in
either growth medium or MSC medium at passage 1. AtThus, the aim of this study was to assess the chondro-
genic differentiation of fetal cells isolated from two fetal 80% confluency, cells were trypsinized and analyzed for
the following surface markers: CD34, CD44, CD45-PE,cartilaginous tissues, fetal femoral head, and fetal spine.
Plasticity of these cells was assessed by analyzing their CD73-PE, CD105-fluorescein, CD166-PE (all from
R&D Systems, Minneapolis, MN, USA, except CD34 andstem cell surface markers and their adipogenic and os-
teogenic differentiation potential. CD73 from BD Bioscience Europe, Erembodegem, Bel-
gium). First, cells were washed in ice-cold PBS and then
MATERIALS AND METHODS incubated with primary antibody in PBS with 2% FBS
Cell Isolation and Culture of Fetal Cells for 30 min at 4°C. For CD34 and CD44 staining, bound
antibodies were visualized by a 30-min incubation atBiopsies for cell isolation were obtained in accor-
dance with the Ethics Committee of University Hospital 4°C with a secondary goat anti-mouse IgG-FITC labeled
antibody (Invitrogen, Switzerland). After ice-cold PBSin Lausanne (Ethical Protocol 51/01). Human fetal spi-
nal column tissues (1 cm length, n = 4: FS12w, FS13w, washing, cells were fixed with 4% PAF at 4°C for 15
min and analyzed with a CyAN ADP Analyser (DaKo-FS14w, FS16w) and human fetal femurs (n = 3, FC14w,
FC16w-a, FC16w-b) were obtained from fetuses after Cytomation, Switzerland) within 24 h. Controls were
performed by substituting primary antibody by isotype-voluntary interruption of pregnancy at 12–16 weeks of
gestation. Biopsies were first rinsed with 1% penicillin/ PE antibody for direct staining and by omitting primary
antibody for indirect staining. Percentage of positivestreptomycin/PBS, cleaned from adjacent tissue, and
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cells was calculated by subtracting control from sample Osteogenic Differentiation
with the Summit software (DaKoCytomation, Switzer- Cells were cultured in growth or MSC medium for
land). fetal cells and in MSC medium only for MSCs until
confluency. Cells were then cultured in growth mediumChondrogenic Differentiation
with 10 mM phosphoglycerol, 200 mg/ml ascorbic acid,
Four hundred thousand fetal cells or BMSCs were and 100 nM dexamethasone for 28 days. At the end of
centrifuged at 400 × g for 5 min to obtain cell pellets. the culture period, cells were washed with PBS, fixed in
Pellets were cultured in chondrogenic medium for 28 4% PAF, washed with distilled water, and stained with
days with renewal of medium twice a week. Chondro- 2% silver nitrate, washed with water, and then with so-
genic medium was made of DMEM supplemented with dium thiosulfate.
1% of 100 mM L-glutamine, 1× insulin-transferrin-sele-
nium (ITS), 10 mM sodium pyruvate, 40 µg/ml L- RESULTS
proline, 50 µg/ml ascorbic acid, and 10 ng/ml transform- Chondrogenic Differentiationing growth factor-3 (TGF-β3). At the end of the culture
Stimulation of BMSCs, fetal spine cells, and femoralperiod, pellets were fixed with 4% PAF, dehydrated
head cells by chondrogenic media led to the productionthrough 70%, 80%, 94%, and 100% ethanol and xylol.
of sulfate-rich matrix as shown by the positive alcianPellets were embedded in paraffin and 7-µm sections
blue staining (Fig. 1). Aggrecan was largely producedwere cut.
by BMSCs, fetal spine cells, and femoral head cells
Histology of Pellet (Fig. 1b). BMSCs produced type II collagen in a specific
region of the pellet, whereas fetal spine and femoralDeparafinized and rehydrated sections of pellets were
head cells produced type II collagen homogenouslystained for 15 min in Weigert’s hematoxylin, stained for
throughout the whole pellet (Fig. 1c). However, two fe-10 min in Alcian Blue (pH 2.5) and molybdic acid for
tal spine cell donors (FS12w and FS13w) produced very10 min, and in Sirius Red for 5 min.
low level or no type II collagen at all. BMSCs produced
Immunohistochemistry of Pellet type I collagen in the whole pellet but a slightly more
intense staining was observed in the type II collagen-Pellet sections were digested with hyaluronidase
positive region (Fig. 1d). Type I collagen was strongly(Sigma, Switzerland) for aggrecan staining and with
produced by three donors of fetal spine cells (FS12w,pepsin (Sigma) for type I, II, and X collagen stainings.
FS13w, FS15w) but the fourth donor (FS14w) showedAfter washing, sections were treated with 0.1% phenyl-
a lower production of type I collagen. All three donorshydrazine (Merck, Switzerland), washed, and blocked in
of fetal femoral head cells produced type I collagen. InPBS containing Triton X-100, FBS, and normal goat se-
both types of fetal cells, a more intense staining for typerum. Sections were then incubated with primary anti-
I collagen was observed at the periphery of the pellets.bodies, aggrecan (1/2000; Biosource, Belgium), type I
Type X collagen was not detected in the BMSC pellets.collagen (5 µg/ml; MP Biomedicals, Switzerland), type
Fetal spine cell donors were heterogenous for type XII collagen (1 µg/ml; Chemicon, Switzerland), and type
collagen production. Type X collagen was detected inX collagen (1/250; Sigma, Switzerland), then washed
the extracellular matrix at a low level in two fetal spineand incubated with goat anti-mouse biotinylated second-
donors (FS12w, FS14w) and it was only detected at theary antibody (Vector Laboratories, USA). After wash-
cellular level in the the other fetal spine cell donorsing, sections were treated with Vectastain ABC kit and
(FS13w, FS15w). On the other hand, fetal femoral headDAB revelation system (Vector Laboratories). Sections
cells showed a high level of type X collagen expressionwere counterstained with Fast Red, dehydrated, and
localized at the cellular and matrix levels. Presence ofmounted for microscopic observation.
enlarged chondrocytes was observed in fetal spine and
Adipogenic Differentiation femoral head pellets.
Cells were cultured in growth or MSC medium for
Expression of Surface Markers by Fetal Spinefetal cells and MSC medium only for MSCs. At conflu-
and Femoral Head Cells at Passage 1ency, cells were treated with growth medium with ITS,
1 µM dexamethasone, 0.1 mM indomethacin, and 0.5 BMSCs cultured in MSC medium were positive for
CD44 (99.2%), CD73 (98.8%; 99.0%), CD105 (76.9%;mM isobutylmethylxanthine. Media was changed twice
a week during 21 days. Then cells were washed with 93.7%), and CD166 (99.4%) and negative for CD34
(2.9%; 5.1%), CD45 (0.2%; 0.4%) (Fig. 2, Table 1). Fe-PBS, fixed in 4% PAF, and stained with Oil Red and
counterstained with Mayer hematoxylin. tal spine and femoral head cells cultured in growth me-
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Figure 1. Chondrogenic differentiation of BMSCs, fetal spine cells, and fetal femoral head cells.
(a) Alcian blue-Weigert-Siruis Red, (b) aggrecan, (c) type II collagen, (d) type I collagen, and (e)
type X collagen stainings. When heterogenous results were obtained among fetal spine or femoral
head cells, lower and higher staining can be seen. Scale bars: 200 µm.
dium showed the same expression pattern and were pos- production of small lipidic vacuoles (Fig. 3Aa, b, d).
Fetal femoral head cells showed more cells positive foritive for CD44 (95.0 ± 2.8; 97.8 ± 0.3), CD73 (98.8 ±
0.8; 98.8 ± 0.2), CD105 (79.1 ± 13.7; 86.7 ± 3.8), and lipidic vacuoles and the size of lipidic vacuoles was
much larger than in fetal spine cells (Fig. 3Aa, c, e). ForCD166 (99.1 ± 0.3; 98.9 ± 0.9) and negative for CD34
(3.9 ± 0.9; 3.9 ± 0.3) and CD45 (2.8 ± 1.2; 1.7 ± 1.5). both types of fetal cells, no difference in the adipogenic
differentiation was observed between growth and BMSCWhen cultured in MSC media, both type of fetal cells
had the same level of expression of surface markers as media conditions. Similar results were obtained when
fetal cells were cultured in DMEM up to passage 4 andthat of in growth media (Table 1).
then treated with adipogenic media (Fig. 3Af, g).
Adipogenic Differentiation of Fetal Cells
Osteogenic DifferentiationFetal cells were cultured in growth or MSC media
and then treated with adipogenic media. BMSCs showed Fetal cells were cultured in MSC media and then
treated with osteogenic media. Fetal spine and femorala high number of adipose vacuole-positive cells, whereas
fetal spine cells in growth or BMSC media showed little head cells produced very low levels of calcium salts
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Figure 2. Representative FACS analysis of CD34, CD44, CD45, CD73, CD105, and CD166 expression of (a) BMSCs, (b) fetal spine cells at passage 1, and (c) fetal femoral
head cells at passage 1. Negative control: gray curve, sample: white curve, positive cells: dashed curve.
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Table 1. Percentage of Positive Cells for CD34, CD44, CD45, CD73, CD105, and CD166 Expression of BMSCs
(n = 2), Fetal Spine Cells (n = 4) at Passage 1 in Growth Media and MSC Media, and Fetal Femoral Head Cells
(n = 3) at Passage 1 in Growth Media and in MSC Media
CD34 CD44 CD45 CD73 CD105 CD166
BMSCs 2.9% 99.2% 0.2% 98.8% 76.9% 99.4%
MSC media 5.1% 99.2% 0.4% 99.0% 93.7% 99.4%
Fetal spine cells passage 1
Growth media 3.9 ± 0.9 95.0 ± 2.8 2.8 ± 1.2 98.8 ± 0.8 79.1 ± 13.7 99.1 ± 0.3
MSC media 4.4 ± 2.9 98.1 ± 1.4 1.3 ± 1.8 99.0 ± 0.6 91.2 ± 10.8 99.5 ± 0.3
Fetal femoral head cells passage 1
Growth media 3.9 ± 0.3 97.8 ± 0.3 1.7 ± 1.5 98.8 ± 0.2 86.7 ± 3.8 98.9 ± 0.9
MSC media 7.7 ± 5.3 91.3 ± 6.0 0.9 ± 0.6 98.4 ± 0.6 85.1 ± 10.9 98.4 ± 1.2
compared with BMSCs (Fig. 3Oa–e). No difference was mechanical and/or physicochemical conditions than fetal
cells. Unexpectedly, type X collagen was not detectedobserved between fetal spine and femoral head cells.
Similar results were obtained when fetal cells were cul- in BMSC pellets as previously described. Chondrogenic
stimulation of MSCs is usually achieved by TGF-β1 ortured in DMEM up to passage 4 and then treated with
osteogenic media (Fig. 3Of, g). -β3 and dexamethasone stimulation in high cell mass
culture (4,21,24,32,45). Although now debated, in this
DISCUSSION model, type X collagen is sequentially induced after in-
duction of type II collagen (4,30,32). It is possible that,In this study, we first examined the TGF-β3-induced
chondrogenic potential of cell populations isolated from in our model, TGF-β3 stimulation was less potent than
in combination with dexamethasone to induce chondro-fetal spine and fetal femoral head. As fetal cells were
isolated from cartilaginous tissues, it was expected that genic differentiation of BMSCs. On the other hand, fetal
spine and femoral head cells may have been more re-they show high chondrogenic property. Alcian blue and
type II collagen staining indicated chondrogenic differ- sponsive to chondrogenic stimulation as they are likely
to be more differentiated than BMSCs. Longer termentiation for BMSCs and fetal cells. However, type II
collagen production by BMSCs was spatially restricted chondrogenic culture and type X expression time course
could give additional information on the developmentwhereas it was homogenous in type II-positive fetal cell
pellets. BMSC populations may be heterogenous for of a hypertrophic phenotype. Fetal femoral head cells
expressed high level of type X collagen, which stronglytype II collagen production or more sensitive to local
Figure 3. Adipogenic (A) and osteogenic (O) differentiation of (a) BMSCs, (b) fetal spine cells at passage 2 in MSC media, (c)
fetal femoral head cells at passage 2 in MSC media, (d) fetal spine cells at passage 2 in growth media, (e) fetal femoral head cells
at passage 2 in growth media, (f) fetal spine cells at passage 4 in growth media, and g) fetal femoral head cells at passage 4 in
growth media. Scale bars: 200 µm.
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suggests that chondrogenic medium induces hypertro- Although additional stem cell surface markers can be
used to refine fetal cell population characterization,phic chondrocyte formation and raises the risk of in vivo
endochondral ossification. This result could be ex- these results strengthen the fact that surface marker
characterization is not enough to predict multilineageplained by the fact that cells from the secondary ossifi-
cation center of the fetal femoral head may have been differentiation potential of cells. In the same way, in’t
Anker et al. showed that isolated fetal MSCs from boneisolated together with cells from the articular cartilage.
Induction of hypertrophy may also be due to the use marrow, liver, lung, and spleen exhibited similar surface
marker expressions but different levels of adipogenicof specific in vitro culture conditions (high cell density,
nonphysiological growth factor concentration), and ossi- and osteogenic differentiation (22). We also noticed that
the two sources of fetal cells had different differentiationfication of these cells should be tested in vivo using un-
differentiated and differentiated cells. On the other hand, potential. Fetal femoral head cells showed a higher adi-
pogenic differentiation potential than fetal spine cells.fetal spine cells showed very little production of type X
collagen. However, cellular positive staining could be Cui et al. reported the presence of MSC-like cells in
fetal articular chondrocyte population (10). These MSC-observed in two fetal spine cell donors (FS13w, FS15w).
These cells may be at an earlier stage where type X like cells could be differentiated into adipose, osteoge-
nic, and neural cells. However, the percentage of differ-collagen has not yet been exported into the extracellular
compartment, which would indicate that these cells are entiated cells was low, likely indicating that most of the
cell population did not show plasticity properties. A veryalso directed toward endochondral ossification. Only the
FS14w cells showed very low level of type X collagen. interesting series of papers demonstrated that adult artic-
ular chondrocyte showed plastic property, and that plas-This difference may be due to the age of the donor or
to a specific cell population. The identification of the ticity increased with passage and time in culture, that is
to say with dedifferentiation level (3,13,39,40). How-cell types present in the fetal spinal cell population
would help to answer this question. Unfortunately, spe- ever, we did not observe an increase plasticity property
of fetal femoral head cells with from passage 2 to 4.cific markers for identification of these cell populations
are not available. The potential clinical use of fetal spine We did not do later passages for these cells because for
potential clinical application, these cells would not nor-cells will not require in vitro differentiation and the use
of growth factor-driven differentiation, possibly alleviat- mally be used after passage 4, but it cannot be excluded
that higher passages of fetal femoral head cells woulding the risk of type X collagen production and endo-
chondral ossification. show higher osteogenic and adipogenic differentiation
properties.In a second part, we examined the plasticity of fetal
cells. Stem cell surface marker expression, and adipo- Further studies, such as clonal selection, are needed
to determine if differentiation properties are due togenic and osteogenic differentiation by fetal cells were
analyzed and compared to those of BMSCs. BMSCs can MSC-like cells or to subpopulation of fetal femoral head
cells with plastic property. Interestingly, very low levelsbe characterized by their ability to self-renew and to dif-
ferentiate into multiple lineages. A panel of surface of adipogenic differentiation were seen with fetal spine
cells. These cells have been isolated from fetal spinemarkers has been developed to isolate and characterize
BMSCs, notably the expression of CD73, CD105, and tissues and are likely to be a mixed population of fibro-
blastic and chondrocytic cells from fetal intervertebralCD166 and the absence of CD34 and CD45. However,
the presence of specific combinations of surface markers disc annulus fibrosus, endplate, and vertebral body. This
difference in plasticity level between spine and femoralis not enough to predict differentiation capacity and dif-
ferentiation protocols are required (14,19). Fetal cells head cells may be related to the origin of the cells. Al-
though fetal spine cells may contain fibroblastic andexhibited similar expression of the studied surface mark-
ers as BMSCs. However, fetal cells had lower adipo- chondrocytic cells from the annulus fibrosus, endplates,
and vertebral body, a homogenous cell population forgenic and osteogenic potential than BMSCs. Culture of
MSCs requires specific culture conditions, such as the all surface markers was seen during the FACS analysis
of the fetal spine cells.presence of FGF, to preserve their multilineage differen-
tiation property whereas fetal cells are routinely cultured In conclusion, chondrogenic stimulation by TGF-β3
of fetal cells isolated from fetal spine and femoral headin growth media, which does not contain any growth
factor (5,37,41). Thus, fetal cells were also cultured in led to the expression of aggrecan and type II collagen
but also of type I and type X collagens. Although fetalMSC media to see if the presence of FGF had an effect
on fetal cell differentiation potential. No effect of FGF cells exhibited a similar expression of stem cell markers
as BMSCs, they showed low plasticity under adipogenicon adipogenic nor for osteogenic differentiation was ob-
served, confirming the observed low plasticity of fetal and osteogenic stimulation. As fetal spine cells showed
lower plasticity and lower endochondral marker expres-cells cultured in growth media.
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